SGLT-2 inhibitors canagliflozin, empagliflozin, and dapagliflozin showed overall comparable effectiveness on cardiovascular outcomes in T2D.
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) and SGLT-2 inhibitors, commonly used for blood sugar control, also offer benefits such as weight loss and reduced inflammation. Although ...
Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers ...
The study revealed a lower risk of nephrolithiasis with SGLT2 inhibitors than DPP4 inhibitors in both stone never-formers and ...
healthday on MSN1d
Age Differences Seen in Efficacy of Type 2 Diabetes TreatmentsAge differences are seen in the efficacy of treatments for type 2 diabetes, according to a study published online Feb ...
A novel transcatheter-implanted system that shunts blood flow from the left to right atrium through the coronary sinus has ...
The Role of Kidney in Glucose Homeostasis — SGLT2 Inhibitors, a New Approach in Diabetes Treatment
SGLT2 inhibitors are a new family of agents ... and glucose reabsorption from proximal convoluted tubule. [1] The purpose of this review paper is to analyze the role of the kidney in glucose ...
Groundbreaking research reveals how common diabetes medications might offer unprecedented protection against heart attacks ...
The global Diabetes Drugs Market size was valued at USD 84.65 billion in 2024 and is expected to be worth around USD 177.74 ...
UK: A recent consensus statement from leading UK medical organizations-including the Association of Anaesthetists,the ...
SGLT-2 inhibitors and GLP-1 receptor agonists are linked to a reduced risk of COPD exacerbations in patients with type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback